Curcumin has the deeper evidence base for joint symptoms — a meta-analysis of eleven meta-analyses found reduced pain and stiffness — but the high-bioavailability formulations that make it work are the ones linked to a growing case series of immune-mediated liver injury. Boswellia's trials are smaller and one meta-analysis found no significant overall effect once heterogeneity was accounted for. Neither modifies the disease.
| Compared on | Curcumin | Boswellia |
|---|---|---|
| Evidence grade | Moderate evidence | Moderate evidence |
| What it is | Curcumin is the principal curcuminoid and yellow pigment of turmeric (Curcuma longa), a rhizome long used as a culinary spice and in traditional medicine. | Boswellia serrata is a branching tree native to India, North Africa and the Middle East whose gum-oleoresin (known as salai guggul and the source of Indian frankincense) has been used for centuries in Ayurvedic medicine to treat inflammatory conditions. |
| Best human evidence | “Pooling 11 meta-analyses, curcuminoid supplementation significantly reduced VAS and WOMAC pain scores and improved joint mobility and stiffness in osteoarthritis patients.” Phytotherapy Research 2024 · PMID 38576215 | “Compared with the control group, Boswellia and its extract may relieve the pain [VAS: (WMD -8.33; 95% CI -11.19, - 5.46; P<0.00001); WOMAC pain: (WMD -14.22; 95% CI -22.34, - 6.09; P = 0.” BMC Complement Med Ther 2020 · PMID 32680575 |
| Dose / protocol studied | Trials are heterogeneous in formulation and dose; the absorption-boosting format matters more than the milligram number on the label. | The key trial tested 100 and 250 mg/day standardized to 30% AKBA; boswellic acids are poorly absorbed, so the specific extract matters. |
| Typical listed price | $28.00 | $19.95 |
| Who it suits | Someone with osteoarthritis symptoms who wants the option with the most convergent meta-analytic support and will monitor liver enzymes on prolonged use. | Someone who wants an NSAID-free option with a fast reported onset and is willing to buy a standardised extract rather than raw resin. |
| Who should skip it | Anyone with liver disease or on hepatotoxic medication without medical advice, and anyone using piperine-boosted formulations long-term without monitoring. | Anyone who wants consistent results — one meta-analysis found no significant overall effect once trial heterogeneity was accounted for. |
| Key caveat | Strongest support is for osteoarthritis symptoms, with modest effects on inflammatory markers, lipids, and depressive symptoms; effect sizes are small and trials are short and heterogeneous in formulation. High-bioavailability products - especially piperine-boosted ones - have been linked to a growing case series of immune-mediated liver injury, so monitoring liver enzymes with prolonged use is prudent. | Trials and meta-analyses show reduced osteoarthritis pain and stiffness, but results are inconsistent - one meta-analysis found no significant overall effect once trial heterogeneity was accounted for. Many trials are small or industry-sponsored, and key boswellic acids are poorly absorbed, so the formulation matters. |
Curcumin lists at about 1.4× the price of Boswellia. Prices are the typical listed prices in our catalog, not live Amazon prices, and a true cost-per-studied-dose is not shown because our catalog does not record servings per container — we would have to guess, so we don't.
Both are anti-inflammatory botanicals with osteoarthritis as the best-studied use. The separation is in trial volume, consistency and safety signal.
Curcumin. Pooling 11 meta-analyses, curcuminoid supplementation significantly reduced VAS and WOMAC pain scores and improved joint mobility and stiffness in osteoarthritis, and a Bayesian network meta-analysis concluded curcumin alone or combined has good clinical efficacy and safety for knee osteoarthritis.
Boswellia. High-bioavailability curcumin products — especially piperine-boosted ones, because piperine inhibits hepatic metabolism — have been linked to a growing case series of immune-mediated liver injury. Monitoring liver enzymes with prolonged use is prudent.
Curcumin. Meta-analyses generally find curcumin/turmeric supplementation lowers CRP, IL-6 and TNF-alpha, though effects on individual cytokines are inconsistent and several analyses report null results.
Boswellia claims the faster onset. Multiple randomized placebo-controlled trials report reduced pain and stiffness and improved joint function, sometimes within days. Independent reviewers describe the evidence as encouraging but not compelling, and many trials are small, industry-sponsored or test proprietary combinations.
Neither compound modifies osteoarthritis. Both act on symptoms, effect sizes are small, and trials are short and heterogeneous in formulation. Reviewers describe both literatures the same way: encouraging, inconsistent, and dependent on the specific extract.
If the target is joint pain rather than inflammation markers, the best-evidenced option on this site is a topical NSAID, which major osteoarthritis guidelines recommend as an early, first-line option.
Each quote below is taken verbatim from the cited paper. Null and negative results are included on purpose — they are the reason a grade means anything.
“Pooling 11 meta-analyses, curcuminoid supplementation significantly reduced VAS and WOMAC pain scores and improved joint mobility and stiffness in osteoarthritis patients.”
“A Bayesian network meta-analysis concluded curcumin, alone or combined, has good clinical efficacy and safety for knee osteoarthritis.”
“curcumin/turmeric supplementation significantly reduces CRP, TNF-alpha, and IL-6”
“Compared with the control group, Boswellia and its extract may relieve the pain [VAS: (WMD -8.33; 95% CI -11.19, - 5.46; P<0.00001); WOMAC pain: (WMD -14.22; 95% CI -22.34, - 6.09; P = 0.”
“Of 20 supplements investigated in 69 studies, seven demonstrated large and clinically important effects for [osteoarthritis] pain reduction at short term.”
“BS supplementation significantly reduced VAS (MD: -10.71; p<0.00001), LFI (MD: -2.99; p<0.00001), WOMAC-pain (MD: -10.69; p<0.0001), WOMAC-stiffness (MD: -5.49; p<0.00001), and WOMAC-function (MD: -10.69; p<0.00001) scores compared to control therapy.”
Links go to an Amazon search for the product name, not to a specific listing, so you can compare sellers, price and third-party testing yourself.
Curcumin has the deeper and more convergent evidence base, including a meta-analysis of eleven meta-analyses. Boswellia's trials are smaller and less consistent, with one meta-analysis finding no significant overall effect once heterogeneity was accounted for.
The absorption-boosting property that makes these products work — often piperine, which inhibits hepatic metabolism — has been linked to a growing case series of immune-mediated liver injury. Monitoring liver enzymes with prolonged use is prudent, and this is a conversation to have with your clinician.
Multiple randomized placebo-controlled trials and several meta-analyses report reduced pain and stiffness and improved function, sometimes within days. But study quality is often low, many trials are industry-sponsored or test combination formulations, and boswellic acids are poorly absorbed, so the specific extract matters.
Many commercial products combine them, and some Boswellia trials tested combination formulations with curcumin — which is one reason the individual evidence is hard to isolate. No trial on this site establishes that the combination is better than either alone.
For the narrow job of raising blood NAD⁺ they look interchangeable — a 2026 randomized trial testing both…
Different jobs. Urolithin A has the better randomized evidence for aging muscle — endurance and strength…
Neither is a proven senolytic in people. Quercetin has the better human data — meta-analyses show a 2–3 mmHg…